Last updated: May 31, 2026
Suppliers for 0.45% sodium chloride (saline) in plastic containers include large sterile-injectables manufacturers and distributors that sell premixed IV fluids into hospitals, distributors, and alternate-care settings. The most reliable procurement channels are (1) branded/authorized product supply from major sterile makers and (2) contracted supply via GPOs and wholesale distributors.
Because “sodium chloride 0.45% in plastic container” is a common IV solution (not a patented specialty drug in most jurisdictions), competitive risk centers on CGMP capacity, supply disruptions, container availability (plastic vs. glass), regulatory listings, and distributor allocation, not on patent exclusivity.
Which companies supply 0.45% sodium chloride IV in plastic containers?
Primary supplier set for 0.45% sodium chloride IV solutions in plastic containers is dominated by large sterile-manufacturing platforms producing generic and contract-available IV fluids under multiple labels and NDCs.
What types of suppliers dominate IV saline procurement?
Tiering that matters for buying decisions:
- Sterile injectables manufacturers: make the solution and package in plastic containers (hospital-grade IV fluids).
- Contract manufacturers / labelers: market the same underlying product under different labels via supply agreements.
- Wholesale distributors: hold inventory and manage allocations during shortages.
- GPO contractors: standardize pricing and product selection across healthcare networks.
Common manufacturer categories buyers see
- US sterile injectables producers supplying through national distribution
- Global sterile fluid makers with US label partners
- Private label / alternate label supply through wholesalers
What container formats are used for 0.45% sodium chloride in plastic?
“Plastic container” for IV saline typically refers to:
- PL 250/PL 300/PL 400-type single-chamber plastic bags (varies by supplier and market)
- Multiple-chamber systems only when combined with other actives, which is less typical for plain 0.45% sodium chloride
Key procurement differentiators
- Bag size (common sizes vary by program and facility protocol)
- Container material and closure (supplier-specific; affects compatibility and handling procedures)
- Sterility assurance testing and release controls (supplier-dependent)
What is the Orange Book status of sodium chloride 0.45% in plastic?
Sodium chloride IV solutions are generally not subject to Orange Book exclusivity the way small-molecule brand drugs are. Procurement and entry risks are therefore driven by:
- CGMP supply continuity
- NDA/ANDA listing status for the specific NDC
- State and federal distribution rules
- Shortage allocation policies
How do you source reliably during saline supply constraints?
During intermittent shortages of IV fluids, sourcing shifts from “who makes it” to “who can allocate it and confirm lead times.”
Practical sourcing paths
- Contracted distribution through major wholesalers with established allocation programs
- GPO-listed SKUs to reduce substitution friction
- Dual-sourcing across bag sizes and NDCs
- Back-up selection of equivalent concentrations and container formats
What can break supply quickly?
- Packaging line downtime (plastic bag formats)
- Raw-material availability (saline components and sterile filtration consumables)
- Regulatory holds at specific manufacturing sites
- Logistics disruptions for bulky IV fluid product
What generic substitution and labeling issues affect sodium chloride 0.45%?
Even when the active ingredient is the same, buyers can face:
- NDC and labeling differences (labeler, bag size, usage instructions)
- Container and closure differences affecting set compatibility
- Stated administration/handling requirements that hospitals must align with policy
Substitution checklist used by procurement teams
- Same concentration: 0.45% sodium chloride (w/v)
- Same route: IV
- Same container: plastic
- Same clinical handling requirements (compatibility guidance, if provided)
Which distributor networks can secure 0.45% sodium chloride?
Supply is usually mediated by national distributors that maintain temperature-controlled and high-throughput logistics for sterile injectables. For procurement planning, buyers typically use:
- Large national wholesalers serving acute care and long-term care
- GPO contract channels that pre-negotiate pricing and substitution terms
- Direct-to-provider supply agreements during constrained periods
Allocation dynamics
- During shortages, wholesalers may allocate by historical usage and/or contracted volume.
- Substitution approvals may be required if the NDC differs.
What documentation should suppliers provide for hospital purchasing?
Hospitals commonly require:
- Certificate of Analysis (CoA) on request or per batch program
- Expiration dating and lot traceability
- Packaging and labeling compliance documentation
- Handling instructions for plastic container IV bags
How does sodium chloride 0.45% compare to 0.9% and 0.225% saline for sourcing?
From a supply standpoint, the key is concentration-specific SKU availability. Even within the same “normal saline family,” procurement can differ because:
- different manufacturing lot scheduling
- different bag configurations and NDCs
- different market demand patterns
Typical procurement behavior
- Many facilities keep multiple concentrations on contract buffers.
- Substitution across concentrations is a clinical decision; concentration is not interchangeable.
What manufacturing/IP barriers exist for sodium chloride 0.45%?
IP barriers are limited for plain IV saline because it is a commodity sterile solution. The real barriers are:
- CGMP manufacturing capacity for sterile liquids
- validated sterilization and filtration processes
- packaging line capacity for plastic bag formats
- quality system throughput (release testing capacity)
Key Takeaways
- 0.45% sodium chloride IV in plastic containers is sourced primarily through major sterile injectables manufacturers and national wholesale distribution networks, not through a narrow patent-protected ecosystem.
- Buyer risk is supply continuity and packaging availability, not long exclusivity timelines.
- Reliable procurement depends on GPO-listed NDCs, distributor allocation programs, dual-sourcing by NDC/bag size, and lot traceability documentation.
- Container and NDC differences can complicate substitution even when concentration is the same.
FAQs
1) What NDCs should I search for when buying 0.45% sodium chloride in plastic bags?
Search by concentration (0.45% sodium chloride), route (IV), and container type (plastic bag) on your hospital formulary system; then verify concentration and bag size on the label.
2) Can I substitute 0.45% sodium chloride with 0.9% saline if 0.45% is out of stock?
Only if the prescribing and clinical protocol allows it; concentration substitution is not automatic and requires clinical approval.
3) Who can provide CoA and lot traceability for 0.45% sodium chloride IV?
Authorized manufacturers or their labelers typically support CoA/traceability; wholesalers can provide lot-level documentation based on batch supply.
4) What causes delays in IV saline availability even for commodity products?
Common causes are sterile manufacturing line downtime, packaging constraints for plastic bags, release testing capacity, and regulatory holds.
5) Are there biosimilar or patent-challenge issues for sodium chloride 0.45%?
For plain saline solutions, competitive dynamics are generally driven by sterile manufacturing supply rather than biosimilar pathways or brand exclusivity/patent challenges.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drug Shortages. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
